*Fate Therapeutics: Cash, Cash Equivalents, and Investments of $139.1 M, Along With Newly Awarded $15M CIRM Grant, Extends the Cash Runway to Mid-2028 >FATE

Dow Jones · 5d ago

Please log in to view news